Stock TNG TRANSGENE
Add to a list
To use this feature you must be a member
Log inSign up

All News Transgene

Equities

TNG

FR0005175080

Real-time Euronext Paris
Other stock markets
 09:40:58 2024-04-26 am EDT 		5-day change 1st Jan Change
1.23 EUR -3.91% Intraday chart for Transgene -11.00% -10.22%
Apr. 10 Transgene: presents vaccine results at AACR CF
Mar. 28 Transgene CFO Steps Down; Successor Assumes Office MT

All News

Search
See the results
Unlock all the news on all businesses: Never miss an investment opportunity again!
100% Free Registration
Availability of Preparatory Documents for the Combined General Meeting of May 15, 2024
GL
Availability of Transgene's 2023 Universal Registration Document
GL
Transgene: presents vaccine results at AACR
CF
Transgene and NEC Present First Clinical Benefits of Neoantigen Cancer Vaccine, TG4050, in Head & Neck Cancer at AACR 2024
GL
Transgene CFO Steps Down; Successor Assumes Office
MT
Transcript : Transgene SA, 2023 Earnings Call, Mar 27, 2024
Transgene anticipates significant progress from immunotherapy pipeline in 2024 and extends financial visibility until Q4 2025
GL
Transgene appoints Lucie Larguier as Chief Financial Officer and Christelle Schwoerer as Chief Human Resources Officer
GL
Transgene SA Reports Earnings Results for the Full Year Ended December 31, 2023
CI
Transgene SA Announces Chief Financial Officer Changes
CI
Transgene SA Promotes Christelle Schwoerer to Chief Human Resources Officer, Effective from April 1, 2024, and She Also Joins the Executive Committee
CI
Transgene Announces Upcoming Investor Meetings
GL
Transgene Announces Upcoming Investor Meetings
AQ
Fractyl Health Reports 'Promising' Preclinical Findings From Rejuva Platform; Shares Fall
MT
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
GL
Transgene to Present New Data on TG4050, an Individualized Cancer Vaccine, at AACR 2024
AQ
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
BU
Transgene, NEC Corporation and BostonGene Corporation Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
CI
Transgene, NEC, and BostonGene Expand Collaboration for Phase I/II Clinical Trial of Neoantigen Cancer Vaccine TG4050
GL
Transgene Appoints Chief Business Officer
MT
No results for this search
All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

Search

Announcement Date

Since

Until

  1. Stock Market
  2. Equities
  3. TNG Stock
  4. News Transgene